Blood Screening Market Share

North American Market Forecast

The blood screening market in North America is projected to be the largest with a share of about 38% by the end of 2037. The higher demand for blood transfusion is forecasted to elevate the market growth in North America during the assessment period. Every year, around 21 million blood components are transfused in the United States. Further, the presence of a strong healthcare network in the region, along with the availability of supportive policies by regulatory bodies, is anticipated to contribute positively to the market's growth.

APAC Market Statistics

The Asia Pacific market is estimated to be the second largest, registering a share of about 25% by the end of 2037. The major factor that is attributed to creating a positive outlook for the market growth is the increasing spending capacity of opting for advanced medical facilities such as blood transfusion diagnostics along with the presence of a high number of medical facilities are also anticipated to hike the market growth further during the projected time frame in the region.

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of blood screening is assessed at USD 3.15 billion.

The blood screening market size was over USD 3 billion in 2024 and is poised to reach USD 6.54 billion by the end of 2037, growing at around 6.3% CAGR during the forecast period i.e., between 2025-2037. Rising number of people suffering with chronic diseases, higher blood transfusions and increased cases of infectious diseases will boost the market growth.

North America is set to be the largest with a industry share of about 38% by 2037, driven by higher demand for blood transfusion in the region.

The major players in the market include Abbott Laboratories, Grifols, S.A., Quotient Limited, Thermo Fisher Scientific Inc., BD, Ortho Clinical Diagnostics, DiaSorin S.p.A., Bio-Rad Laboratories, Inc., Danaher Corporation, Beckman Coulter, Inc.

Blood Screening Market Share